A Phase 2 interventional study of Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP and Biopsy Procedure in Colorectal Carcinoma, EPCAM Lynch Syndrome and Lynch Syndrome, sponsored by National Cancer Institute (NCI). Not yet recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by National Cancer Institute (NCI) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in United States — 21 open to participants now, 33 under way, 2 of them phase 3. Colorectal Neoplasms, Hereditary Nonpolyposis · United States.
Among the 72 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in United States, this one is the 30th largest by planned enrollment of the 43 interventional ones that give a count, is the only one that started in 2027, is one of 6 in phase 2, reaches primary completion later than 27 of the 32 other live ones, and was the 72nd registered.
147 studies on the registry are indexed under Colorectal Neoplasms, Hereditary Nonpolyposis; 60 are open to participants now.
Browse Colorectal Neoplasms, Hereditary Nonpolyposis studies →21 of the 72 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in United States are open now. Recruiting first, the newest first:
Vividion Therapeutics, Inc. · Sites in United States, Argentina, Belgium and 19 more countries
Ages 18+
Jessica D. St. Laurent, MD · Sites in United States
Ages 18+ · Women only · Healthy volunteers
University of Alabama at Birmingham · Sites in United States
Ages 18+ · Healthy volunteers
University of Chicago · Sites in United States
Ages 20–80
University of Colorado, Denver · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Colorectal Neoplasms, Hereditary Nonpolyposis studies recruiting now, 32 (74%) set no upper age limit and 4 (9%) stop at 75 or younger; 4 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 2
First in 1994; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 55 is below the median of 200 across 76 interventional studies indexed under Colorectal Neoplasms, Hereditary Nonpolyposis.
Median enrollment 162 across the 43 interventional studies, 300 across the 29 observational. Of the 32 that completed or were terminated, 7 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 72 have an industry lead sponsor. The 10 most frequent:
National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 336 are open to participants now.
Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.
National Cancer Institute (NCI) has 8 studies filed under Colorectal Neoplasms, Hereditary Nonpolyposis — fewer than ten, so there is no comparison to draw.
8 of the studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00582296Memorial Sloan Kettering Cancer CenterMulti-Organ Screening Recommendations in Patients With Lynch Syndrome | 2026-12 |
| NCT02371135Memorial Sloan Kettering Cancer CenterMetagenomic Evaluation of the Gut Microbiome in Patients With Lynch Syndrome and Other Hereditary Colonic Polyposis Syndromes | 2027-02 |
| NCT07220239Jessica D. St. Laurent, MDMenstrual Cup for Early Endometrial Cancer Detection in Lynch Syndrome | 2027-03 |
| NCT05692596H. Lee Moffitt Cancer Center and Research InstituteThe Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics | 2027-07 |
| NCT05419011National Cancer Institute (NCI)Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome | 2027-07-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 72 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This phase II trial studies how well a vaccine called Nous-209 works in reducing the size of abnormal area of tissue growth or polyps (colorectal lesions) in patients with Lynch syndrome. When patients have Lynch syndrome, errors in the genetic information inside cells are not properly corrected. When that happens, the cells produce new proteins called neoantigens. Nous-209 is a vaccine with man-made copies of neoantigens combined with viral vectors. Neoantigens are new proteins that form inside tumor cells when certain mutations occur inside them. The body's immune system recognizes these proteins as foreign and generates a response against the tumor cell that produced the neoantigen. Giving the Nous-209 vaccine may be able to reduce the size of existing colorectal lesions (polyps) that were 5 to 15 mm in diameter at the time of patients' first colonoscopy or flexible sigmoidoscopy.
PRIMARY OBJECTIVE:
I. To assess the effect of adenoviral tumor-specific neoantigen priming vaccine GAd-209-FSP and modified vaccinia Ankara virus (MVA) tumor-specific neoantigen boosting vaccine MVA-209-FSP (Nous-209) on the participant-level response rate based on the change from baseline to week 16 in the size of qualified colorectal lesions that are greater than or equal to 5 mm and less than or equal to 15 mm in diameter detected at the baseline lower gastrointestinal (GI) endoscopy (change of the cumulative size of lesions per trial participant).
SECONDARY OBJECTIVES:
I. To assess the effect of Nous-209 on the change in the size of colorectal lesions that are greater than or equal to 5 mm and less than or equal to 15 mm in diameter detected at the baseline lower GI endoscopy to week 16, regardless of mismatch repair (MMR) status (analysis of all lesions observed in the study within this size range).
II. To assess the development of new lesions during the treatment period defined as lesions identified at week 16 that were not observed at the baseline lower GI endoscopy (incidence of new lesions at week 16).
III. To assess the development of new lesions defined as lesions identified at month 16 that were not observed at the lower GI endoscopy at week 16 (incidence of new lesions at month 16).
IV. To assess the effect of Nous-209 on the change in the size of colorectal lesions that are less than 5 mm and greater than 15 mm in diameter detected at week 16 and at month 16 lower GI endoscopy.
V. To assess the safety of Nous-209 in the clinical trial participants for the duration of the study (16 months).
VI. To evaluate the immunogenicity of Nous-209 post-vaccination using enzyme-linked immunosorbent spot assay (ELISpot) and other immunological assays in trial participants at week 16 and at month 16.
EXPLORATORY OBJECTIVES:
I. To assess the effect of Nous-209 on the change in the size of mismatch repair deficient (MMRd) colorectal lesions that are greater than or equal to 5 mm and less than or equal to 15 mm in diameter detected at the baseline lower GI endoscopy to week 16 determined by immunohistochemistry (IHC) performed in the biopsy/resection tissue obtained at end-of-study lower GI endoscopy (analysis of MMRd lesions only).
II. To assess changes post- versus (vs) pre-vaccination of levels of T cell infiltration, T cell immune-profile, T cell receptor (TCR) repertoire, and pathological features including presence/absence of dysplasia in colorectal lesions (for the entire duration of the trial).
III. To assess changes in peripheral blood T cell immune-profile and TCR repertoire induced by vaccination with Nous-209 in trial participants (for the entire duration of the trial).
IV. To assess changes post- vs pre-vaccination of levels of T cell infiltration, T cell immune-profile, TCR repertoire, and pathological features in normal colorectal mucosal biopsies adjacent to detected colorectal lesions (for the entire duration of the trial).
V. To assess vaccine-induced T-cell cytotoxicity on matched patient-derived colorectal lesions and normal mucosa organoids (for the entire duration of the trial).
OUTLINE:
Patients receive adenoviral tumor-specific neoantigen priming vaccine GAd-209-FSP (GAd20-209-FSP) intramuscularly (IM) at week 0 (day 1) followed by MVA tumor-specific neoantigen boosting vaccine MVA-209-FSP (MVA-209-FSP) IM at week 8 in the absence of disease progression or unacceptable toxicity. Patients also undergo colonoscopy or flexible sigmoidoscopy, tissue biopsies, and blood sample collection throughout the study.
After completion of study intervention, patients are followed up at weeks 9 and 16, and then months 8, 12, and 16.
147 studies on the registry are indexed under Colorectal Neoplasms, Hereditary Nonpolyposis; 60 are open to participants now.
This study's planned enrollment of 55 is below the median of 200 across 76 interventional studies indexed under Colorectal Neoplasms, Hereditary Nonpolyposis.
Browse Colorectal Neoplasms, Hereditary Nonpolyposis studies →National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 336 are open to participants now.
Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.
Compared within Colorectal Neoplasms, Hereditary Nonpolyposis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Colorectal Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive GAd20-209-FSP IM at week 0 (day 1) followed by MVA-209-FSP IM at week 8 in the absence of disease progression or unacceptable toxicity. Patients also undergo colonoscopy or flexible sigmoidoscopy, tissue biopsies, and blood sample collection throughout the study.
Biological: Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP · Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Colonoscopy · Biological: MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP · Procedure: Sigmoidoscopy
Given IM
Also known as: GAd-209-FSP, GAd20-209-FSP, Great Ape Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP
Undergo tissue biopsies
Also known as: Biopsy, BIOPSY_TYPE, Bx
Undergo blood sample collection
Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection
Undergo colonoscopy
Given IM
Also known as: Modified Vaccinia Ankara Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP, Modified Vaccinia Virus Ankara Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP, MVA-209-FSP
Undergo flexible sigmoidoscopy
Also known as: Proctosigmoidoscopy
Participant-level response rate
Will be based on the change from baseline to week 16 in the size of colorectal lesions that are greater than or equal to 5 mm and less than or equal to 15 mm in diameter detected at the baseline lower gastrointestinal (GI) endoscopy (change of the cumulative size of lesions per trial participant). The participant-level response rate will be estimated along with its one-sided 95% confidence interval, which will be constructed assuming the exact binomial distribution. All primary analyses will be conducted at the participant level. New lesions detected at week 16 will be included in the primary endpoint analysis. When calculating the change in cumulative lesion diameter from baseline to week 16, the baseline diameter of a new lesion detected at Week 16 would be considered zero.
Time frame: Baseline to week 16
Change in the size of colorectal lesions that are greater than or equal to 5 mm and less than or equal to 15 mm, regardless of mismatch repair (MMR) status
Will be evaluated using mixed-effects models, with participant included as a random effect to account for correlation among multiple lesions within the same participant. Analyses of MMR deficient (MMRd) lesions will be conducted similarly among lesions with available MMR status.
Time frame: Baseline to week 16
Development of new colorectal lesions
Defined as lesions identified at week 16 that were not observed at the baseline lower GI endoscopy (incidence of new lesions at week 16). Will be summarized by the number and percentage of participants with at least one new lesion.
Time frame: Baseline to week 16
Development of new colorectal lesions
Defined as lesions identified at month 16 that were not observed at the baseline lower GI endoscopy (incidence of new lesions at month 16). Will be summarized by the number and percentage of participants with at least one new lesion.
Time frame: Baseline to month 16
Change in the size of colorectal lesions that are < 5 mm and > 15 mm in diameter
Will be evaluated using mixed-effects models, with participant included as a random effect to account for correlation among multiple lesions within the same participant. Analyses of MMRd lesions will be conducted similarly among lesions with available MMR status.
Time frame: Baseline up to month 16
Incidence and severity of adverse events
Safety endpoints will be summarized in tabular format by type, severity, and attribution. Safety endpoints will be summarized by frequency and percentage, including rates of grade 2/3 adverse events and grade 2-5 adverse events.
Time frame: Up to 16 months
Immunogenicity of Nous-209
Will be evaluated using enzyme-linked immunosorbent spot assay and other immunological assays.
Time frame: Baseline up to 16 months
Change in the size of MMRd colorectal lesions that are greater than or equal to 5 mm and less than or equal to 15 mm in diameter
Assessed in lesions detected at the baseline lower GI endoscopy determined by immunohistochemistry performed in the biopsy/resection tissue obtained at end-of-study lower GI endoscopy (analysis of MMRd lesions only).
Time frame: Baseline up to month 16
Changes of levels of T cell infiltration, T cell immune-profile, T cell receptor (TCR) repertoire, and pathological features
Will assess changes post- versus pre-vaccination of levels of T cell infiltration, T cell immune-profile, TCR repertoire, and pathological features including presence/absence of dysplasia in colorectal lesions (for the entire duration of the trial). Will be analyzed descriptively. Changes over time will be evaluated using the longitudinal modeling, as appropriate.
Time frame: Baseline up to month 16
Changes in peripheral blood T cell immune-profile and TCR repertoire induced by vaccination with Nous-209
Will be analyzed descriptively. Changes over time will be evaluated using the longitudinal modeling, as appropriate.
Time frame: Baseline up to month 16
Changes of levels of T cell infiltration, T cell immune-profile, TCR repertoire, and pathological features in normal colorectal mucosal biopsies adjacent to detected colorectal lesions
Will be analyzed descriptively. Changes over time will be evaluated using the longitudinal modeling, as appropriate.
Time frame: Baseline up to month 16
Vaccine-induced T-cell cytotoxicity on matched patient-derived colorectal adenoma and normal mucosa organoids
Will be analyzed descriptively. Changes over time will be evaluated using the longitudinal modeling, as appropriate.
Time frame: Baseline up to month 16
Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Data sharing details ↗ · grants.nih.gov
No publications or documents are linked to this record.
Start is estimated for Apr 2027; primary completion for Nov 2031, 55 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP
Colorectal Neoplasms, Hereditary Nonpolyposis →
National Cancer Institute (NCI) →